Academic Journals Database
Disseminating quality controlled scientific knowledge

Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation

ADD TO MY LIST
 
Author(s): Nitsan Maharshak | Philippe Halfon | Varda Deutsch | Hava Peretz | Shlomo Berliner | Sigal Fishman | Shira Zelber-Sagi | Uri Rozovski | Moshe Leshno | Ran Oren

Journal: World Journal of Gastroenterology
ISSN 1007-9327

Volume: 17;
Issue: 45;
Start page: 5007;
Date: 2011;
Original page

Keywords: Hepatitis C virus | Liver fibrosis | Hypercoagulation | Prothrombin 20210

ABSTRACT
AIM: To examine whether hepatitis C virus (HCV)-infected patients who carry hypercoagulable mutations suffer from increased rates of liver fibrosis. METHODS: We analyzed DNA samples of 168 HCV patients for three common hypercoagulable gene mutations: prothrombin 20210 (PT20210), factor V Leiden (FV Leiden) and methylene tetrahydrofolate reductase (MTHFR). The patients were consecutively recruited as part of the prospective “Fibroscore Study” in France. The effect of the various mutations on the rate of fibrosis was analyzed statistically and was correlated with epidemiological, clinical and biochemical data such as grade and stage of liver biopsies, patients’ risk factors for liver cirrhosis, and timing of infection. RESULTS: Fifty two of the patients were categorized as “fast fibrosers” and 116 as “slow fibrosers”; 13% of the “fast fibrosers” carried the PT20210 mutation as compared with 5.5% of the “slow fibrosers”, with an odds ratio of 4.76 (P = 0.033; 95% CI: 1.13-19.99) for “fast” liver fibrosis. Carriage of MTHFR or FV Leiden mutations was not associated with enhanced liver fibrosis. CONCLUSION: Carriage of the PT20210 mutation is related to an increased rate of liver fibrosis in HCV patients.
Why do you need a reservation system?      Affiliate Program